Precision BioSciences Inc

NASDAQ:DTILUnited States

Apr 16, 2024

Show headlines and story abstract

• Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration, from 5:30PM ET on Tuesday Apr 16, 2024 by MT Newswires

  5:30PM ET on Tuesday Apr 16, 2024 by MT Newswires
  Companies Mentioned: LLY, DTIL
  05:30 PM EDT, 04/16/2024 (MT Newswires) -- Precision BioSciences (DTIL) said late Tuesday it exercised the option to regain rights for three programs following Eli Lilly (LLY) unit Prevail Therapeutics' decision to conclude a gene-editing collaborat...

• DJ Precision BioSciences to Regain Programs After Prevail Team-Up Ends, from 4:52PM ET on Tuesday Apr 16, 2024 by Dow Jones

  4:52PM ET on Tuesday Apr 16, 2024 by Dow Jones
  Companies Mentioned: LLY, DTIL
  
  By Dean Seal
  
  Precision BioSciences expects to get three programs back from Prevail Therapeutics after a gene-editing collaboration between the two companies ended.
  
  

• Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics, from 4:15PM ET on Tuesday Apr 16, 2024 by Business Wire

  4:15PM ET on Tuesday Apr 16, 2024 by Business Wire
  Companies Mentioned: DTIL

  --- Precision exercised option to regain control of programs and intends to bring collaboration programs back to develop independently or with new partners

  --- Precision's most important near-term clinical priorities in Hepatitis B (HBV) and Primary Mitochondrial Myopathy (PMM) and the expected cash runway into the second half of 2026 are not impacted

• Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics, from 4:15PM ET on Tuesday Apr 16, 2024 by Dow Jones

  4:15PM ET on Tuesday Apr 16, 2024 by Dow Jones
  Companies Mentioned: DTIL
  
  achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators' or other licensees' ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators' or other licensees' development of product candidates; our or our collaborators' or other licensees' ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; our ability to obtain an adequate supply of T cells from qualified donors; delays or difficulties in our and our collaborators' and other licensees' ability to enroll patients; changes in interim "top-line" and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees' ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators' or other licensees' ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of the COVID-19 pandemic and variants thereof, or any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at www.sec.gov and the Investors page of our website under SEC Filings at investor.precisionbiosciences.com.